Primer Fibromiyalji Sendromunda Oral Magnezyum Tedavisinin Etkinliği
AMAÇ:Bu çalışmanın amacı, primer fibromiyalji sendromu olan hastalarda oral magnezyum tedavisinin hassasnokta sayısı, ağı şiddeti gibi klinik bulgular ve fonksiyonel kapasite üzerine olan etkilerini araştırmaktır.GEREÇ ve YÖNTEMLER:Yirmi-beş primer fibromiyalji sendromu olan hasta (24 bayan 1 erkek) çalışmayadahil edildi. Hastalar istirahat ve aktivite ağrıları, hassas nokta sayısı ve fonksiyonel kapasite açısındandeğerlendirildi. Fibromiyalji etkinlik sorgulaması ve vizuel analog skala (VAS), sırasıyla fonksiyonel durum veağrı şiddetini değerlendirmek için kullanıldı. Serum ve 24 saatlik idrarda magnezyum seviyesi ölçüldü. Serum veidrar magnezyum düzeyleri Abbott Aeroset autoanaylzer orjinal kiti (Abbott Laboratories, Abbott Park, IL,60064, USA) ile ölçüldü. Hastalar iki ay boyunca magnezyum sitrat (Magnesium Diasporal 600 mg saşe b.i.d.oral) tedavisi aldılar. İki ayın sonunda, tekrar muayene edilip klinik bulguları kaydedildi.BULGULAR:Hastaların yaş ortalaması 44.8 (SS=7.4) yıl ve hastalık süresi ortalama 25.4 (SS=19.2) aydı.Hassas nokta sayısı, ağrı ve fibromiyalji etkinlik sorgulaması skorunda tedavi öncesine göre ikinci ayın sonundaanlamlı iyileşme olduğu gözlendi (p0.05).SONUÇ:Fibromiyalji sendromunun tedavisinde magnezyum sitrat tedavisi hassas nokta sayısı, ağrı vefonksiyonel durum üzerinde etkili ve güvenli olarak bulundu
EFFICACY of ORAL MAGNESIUM TREATMENT on PRIMARY FIBROMYALGIA SYNDROME
Objective: The aim of this study was to investigate the effects of oral magnesium treatment on clinical findings such as number of sensitive points, severity of pain and functional capacity in primary Fibromyalgia syndrome patients. Material and Methods: Twenty-five primary fibromyalgia syndrome patients (24 female, 1 male) were enrolled to the study. Patients were examined in terms of pain in rest and activity, number of sensitive points and functional capacity. Fibromyalgia Impact Questionnaire and Visual Analogue Scale (VAS) were used for functional assessment and pain respectively. Serum and twenty-four hour urine magnesium levels were measured. The serum and urine magnesium levels were measured by original kits of Abbott Aeroset autoanaylzer (Abbott Laboratories, Abbott Park, IL, 60064, USA). Patients were administered magnesium citrate (Magnesium Diasporal 600 mg sachets b.i.d. orally) therapy for two months. At the end of two months, patients were reexamined in terms of recorded clinical and laboratory findings. Results: The mean age of patients was 44.8 (SD=7.4) years and the mean duration of disease was 25.4 (SD=19.2) months. There was a significant improvement in number of sensitive points, pain and Fibromyalgia Impact Questionnaire score at the end of two-month therapy (p0.05). Conclusions: In the treatment of Fibromyalgia syndrome, magnesium citrate therapy was found to be safe and efficient on number of sensitive points, pain and functional state.
___
- 1. Bennett RM. The Fibromyalgia Syndrome. In: Kelley
WN, Haris ED, Ruddy S, Sledge CB, editors. Textbook
of rheumatology. Philadelphia: WB Saunders
Company 1997:511-9.
- 2. Wolfe F, Ross K,Anderson J, Russell IJ, Herbert L. The
prevalence and characteristics of fibromyalgia in the
general population.Arthritis Rheum 1995; 38:1928.
- 3. Krsnich-Shriwise S. Fibromyalgia syndrome: An
overview. Phys Ther 1997;77:68-75.
- 4. Romano TJ, Stiller JW. Magnesium deficiency in
fibromyalgia syndrome. J Nutr Med 1994;4:165-7.
- 5. Wolfe F, Smythe HA, Yunus MB, Bennett RM,
Bombardier C, Goldenberg DL, et al. American
Rheumatology criteria for classification of
fibromyalgia: report of the Multicenter Criteria
Committee.Arthritis Rheum 1990;33: 160-72.
- 6. Burckhardt CS, Clark SR, Bennett RM. The
fibromyalgia impact questionnaire: development and
validation. J Rheumatol 1991;18:728-34.
- 7. Sarmer S, Ergin S, Yavuzer G. The validity and
reliability of the Turkish version of the fibromyalgia
impact questionnaire. Rheumatol Int 2000;20: 9-12.
- 8. Percival M. Fibromyalgia Nutritional Support.
Clinical Nutritional Insights 1997:3.
- 9. Heaton FWY. Magnesium deficiency and membrane
properties. In: Altura BM, Durlach J, Seelig MS,
editors. Magnesium in cellular processes and medicine.
Basel: Karger 1987:121-30.
- 10. Yunus MB, Raman KIUP, Raman KK. Primary
fibromyalgia syndrome and myofacial pain syndrome:
Clinical features and muscle pathology.Arch Phys Med
Rehabil 1988;69:451-4.
- 11. Johansson BW. Magnesium infusion in decompensated
hypomagnesaemia patients. Acta Pharmacol Toxicol
(Copen) 1984;54:125-8.
- 12. Cox IM, Campbell MJ, Dowson D. Red blood cell
magnesium and chronic fatigue syndrome. Lancet
1991;337:747-60.
- 13. Galland L. Magnesium and inflammatory bowel
disease. Magnesium 1988;7:78-83.
- 14. Durlach J, Lutfalla G, Poenaru S, Reba A, Henrotte JG,
Fabiani F, et al. Latent tetany and mitral valve prolapse
due to chronic primary magnesium deficit. In: Halpern
MJ, Durlach J, editors. Magnesium defiency. Basel:
Karger 1985:102-12.
- 15. Galland L. Magnesium defiency in mitral valve
prolapse. In: Halpern MJ, Durlach J, eds. Magnesium
defiency. Basel: Karger 1985:117-19.
- 16. Fernandes JS, Pereira T, Alcazar A, Franca A, Andrade
R, Pereira JN, et al. Idiopathic mitral valve prolapse and
the neuromuscular form of primary magnesium deficit.
In: Halpern MJ, Durlach J, editors. Magnesium
defiency. Basel: Karger. 1985:120-1.
- 17. Altura BM. Calcium antagonist properties of
magnesium: implications for antimigraine actions.
Magnesium 1985;4:169-75.
- 18. Abraham GE. Primary dysmenorrhea. Clin Obs Gyn
1978;21:139.
- 19. Abraham GE, Flechas JD. Management of
fibromyalgia: Rationale for the use of magnesium and
malicAcid. J Nutr Med 1992;3:49-59.
- 20. Eisinger J, Zakarian H, Pouly E, Plantamura A, Ayavou
T. Protein peroxidation, magnesium deficiency and
fibromyalgia. Magnes Res 1996; 9(4):313-6.
- 21. Eisinger J, Plantamura A, Marie PA, Ayavou T.
Selenium and magnesium status in fibromyalgia.
Magnes Res 1994;7(3-4):285-8.
- 22. Magaldi M, Moltoni L, Biasi G, Marcolongo R.
Changes in intracellular calcium and magnesium ions
in the physiopathology of the fibromyalgia syndrome.
Minerva Med 2000;91(7-8):137-40
- 23. Prescott E, Norrgard J, Rotbol Pedersen L,
Danneskiold-Samsoe B. Fibromyalgia and magnesia.
Scand J Rheumatol 1992;21(5): 264.
- 24. Goldenberg DL. Fibromyalgia, chronic fatigue
syndrome, and myofascial pain syndrome. Curr Opin
Rheumatol 1997;9(2):135-43.
- 25. Keenoy BM, Moorkens G, Vertommen J, Noe M, Neve
J, De Leeuw I. Magnesium status and parameters of the
oxidant-antioxidant balance in patients with chronic
fatigue: effects of supplementation with magnesium. J
Am Coll Nutr 2000;19(3):374-82.
- 26. Clague JE, Edwards RHT, Jackson MJ. Intravenous
magnesium loading in chronic fatigue syndrome.
Lancet 1992;340: 124-5
- 27. Wahner-Roedler DL, Eklin PL, Vincent A, Thompson
JM, Oh TH, Loehrer LL, et al. Use of complementary
and alternative medical therapies by patients referred to
a fibromyalgia treatment program at a tertiary care
center. Mayo Clin Proc 2005; 80(1):55-60.
- 28. Holdcraft LC, Assefi N, Buchwald D. Complementary
and alternative medicine in fibromyalgia and related
syndromes. Best Pract Res Clin Rheumatol
2003;17(4):667-83.
- 29. Sarac AJ, Gur A. Complementary and alternative
medical therapies in fibromyalgia. Curr Pharm Des
2006;12(1):47-57.